Covid19 Clinical Trial
— PGE1-COVID19Official title:
Effectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19
Verified date | September 2023 |
Source | Fundación Santa Fe de Bogota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Clinical trial aim to evaluate the effectiveness and safety of the administration of the intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized clinical trial in the Fundación Santa Fe de Bogota
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 3, 2020 |
Est. primary completion date | December 3, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient older than 18 years of age - COVID19 diagnosis: - RT PCR for COVID-19 positive in respiratory tract sample (nasopharyngeal swab, sputum, bronchoalveolar lavage) - At least 2 of the following symptoms: cough, odynophagia, dyspnea, asthenia, adynamia, gastrointestinal symptoms. - Findings compatible with viral pneumonia on chest tomography or chest radiography. - Risk of respiratory deterioration given by at least 1 of the following: - Hypoxemia: PaO2 <60 mmHg, SaO2 <90% or supplemental O2 requirement to maintain SaO2> 90% - Call Score = 9 points - FR> 30 / min - PaO2 / FiO2 less than 200 - Intubated patients without deterioration of other organs (without acute kidney injury, without elevated transaminases). - Progression of radiological findings of pneumonia. - Patients with moderate or severe oxygenation disorder, with diaphragm of 200-100 and <100 respectively, who require supplemental oxygen at high flow (non-rebreathing mask or high flow cannula). - Complete record of medical history, allergies, and medical conditions that preclude the use of prostaglandin E1 analogs have been ruled out. - Voluntary participation in the study, demonstrating fullness through informed consent. Exclusion Criteria: 1. Allergy or sensitivity to PEG1 analog or components 2. Arterial hypotension defined as blood pressure less than 90/60 mm of mercury or mean arterial pressure less than 65mm of mercury or BP requirement <80/50 mmHg or TAM 60 mmHg with norepinephrine requirement greater than 0.1 mcg / kg / min 3. Severe hypertension defined as systolic blood pressure greater than or equal to 180 mm of mercury and / or diastolic blood pressure greater than or equal to 110 mm of mercury 4. Bradycardia defined as heart rate less than 60 beats per minute 5. Previous events of priapism or penile anatomical changes 6. Sickle cell disease, multiple myeloma, leukemia, polycythemia vera, thrombocythemia predisposing to priapism 7. Hemorrhagic diathesis 8. Active peptic ulcer, trauma, or recent brain hemorrhage. 9. Abnormal pulmonary venous return with obstruction 10. Pregnancy: A pregnancy test will be performed upon admission of the patient to the study (if applicable). 11. Heart failure with NYHA functional class> 1 12. Hemodynamically relevant arrhythmia: That generates hypotension, chest pain, dysfunction, sensory disturbance or other signs of low output 13. Mitral and / or aortic stenosis and / or insufficiency of either 14. Unstable angina 15. Acute Myocardial Infarction in the last 6 months 16. Ischemic or hemorrhagic cerebrovascular event in the last 6 months 17. Child B or C or decompensated liver cirrhosis 18. Chronic kidney disease in renal replacement therapy 19. Serious medical condition or laboratory findings that, in the investigator's judgment, may compromise patient safety during participation in the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Alonso Vera Torres |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | Death during or at the end of the intervention | 6 month | |
Secondary | Hypoxemia Resolution | Sat O2> 90% to the environment | 6 month | |
Secondary | Days from admission to intensive care unit and administration of ANALOG PGE1 | Number of days from admission to intensive care unit until administration of ANALOG PGE1 | 6 month | |
Secondary | ICU stay | Specify number of days of ICU stay | 6 month | |
Secondary | Days with high flow oxygen | Record days that the patient has received oxygen through a high flow system | 6 month | |
Secondary | Days of invasive mechanical ventilation prior to administration of PGE1 ANALOG | Number of days during which the patient was under invasive or non-invasive mechanical ventilation prior to the administration of PGE1 ANALOG | 6 month | |
Secondary | Evolution time of the disease | Time from the onset of symptoms to the day of admission | 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |